FDA Brief: Week of Mar 14, 2016

fda guidances


 

zika_GzikaGuidance : To reduce risk of transfusion-tranmission of Zika Virus

  • For blood establishments that collect whole blood and blood components for donor screening, donor deferral and product management
  • Zika is an arbovirus; transmitted to humans primarily by mosquito, intrauterine, perinatal and sexual transmission have been reported
  • Risk of transmission by blood transfusion is considered likely based on case reports, viremia, pre-symptomatic periods, positive blood donation reports
  • Recommendations provided for
    • For Areas without Active Transmission
    • For Areas with Active Transmission
    • Post-Donation Information and Product Management
    • Product Disposition and Labeling

READ

Q&A for Guidance

  • Answers to common questions from blood establishments
  • To assist blood establishments in implementing the guidance recommendations

READ


NIH_FDA

  • Clinical Trial Protocol Template for  IND trials (drugs) or IDE trials (Devices)
  • For trials supported by the National Institutes of Health (NIH)
  • Investigators  strongly encouraged to use template; meets ICH standards
  • For Public Comment

READ


 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s